Literature DB >> 9550370

Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation.

D López1, M Del Val.   

Abstract

CTL recognize peptides derived from protein Ags bound to MHC-class I molecules. Proteasomes probably participate in the generation of these peptide epitopes. We investigated the role of proteasomes in the presentation of endogenously synthesized short viral proteins. To this end, we employed proteasome and cysteine protease inhibitors and two closely related recombinant vaccinia viruses that code for 17- and 19-amino acid-long products encompassing murine CMV 9pp89 epitope. Presentation of both minigene products required processing to shorter peptides and was independent of ubiquitination. Proteasomes were necessary for processing the 17-mer product, and cysteine proteases were not required. In contrast, the 19-mer product could be processed in parallel either by proteasomes or by cysteine proteases independently. These results highlight the diversity of alternative processing pathways even for short peptidic Ags, provide evidence for the involvement of cysteine proteases in MHC class I presentation, and show that cleavage by cysteine proteases is governed by sequences flanking the epitope.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9550370

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity.

Authors:  A Castilleja; N E Ward; C A O'Brian; B Swearingen; E Swan; M A Gillogly; J L Murray; A P Kudelka; D M Gershenson; C G Ioannides
Journal:  Mol Cell Biochem       Date:  2001-01       Impact factor: 3.396

2.  Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3.

Authors:  D Valmori; U Gileadi; C Servis; P R Dunbar; J C Cerottini; P Romero; V Cerundolo; F Lévy
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

3.  Caspases in virus-infected cells contribute to recognition by CD8+ T lymphocytes.

Authors:  Daniel López; Margarita García-Calvo; Geoffrey L Smith; Margarita Del Val
Journal:  J Immunol       Date:  2010-03-26       Impact factor: 5.422

4.  Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation.

Authors:  Roger Belizaire; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-25       Impact factor: 11.205

5.  Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins.

Authors:  J D Lich; J F Elliott; J S Blum
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

6.  alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.

Authors:  Emmanuelle Godefroy; Agnes Moreau-Aubry; Elisabeth Diez; Brigitte Dreno; Francine Jotereau; Yannick Guilloux
Journal:  J Exp Med       Date:  2005-07-04       Impact factor: 14.307

7.  Variable processing and cross-presentation of HIV by dendritic cells and macrophages shapes CTL immunodominance and immune escape.

Authors:  Jens Dinter; Ellen Duong; Nicole Y Lai; Matthew J Berberich; Georgio Kourjian; Edith Bracho-Sanchez; Duong Chu; Hang Su; Shao Chong Zhang; Sylvie Le Gall
Journal:  PLoS Pathog       Date:  2015-03-17       Impact factor: 6.823

8.  Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin.

Authors:  B C Gil-Torregrosa; A Raúl Castaño; M Del Val
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

9.  Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.

Authors:  Judy Tellam; Geoff Connolly; Katherine J Green; John J Miles; Denis J Moss; Scott R Burrows; Rajiv Khanna
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.